**OPTIMISATION PROGRAMME OF OMALIZUMAB TREATMENT FOR CHRONIC IDIOPATHIC URTICARIA**

1. HOSPITAL UNIVERSITARIO PUERTO REAL, PHARMACY, PUERTO REAL, SPAIN
2. HOSPITAL GENERAL NUESTRA SEÑORA DEL PRADO, PHARMACY, TALAVERA DE LA REINA, SPAIN
3. HOSPITAL UNIVERSITARIO DE PUERTO REAL, PHARMACY, PUERTO REAL, SPAIN
4. HOSPITAL UNIVERSITARIO DE PUERTO REAL, DERMATOLOGY, PUERTO REAL, SPAIN.

---

**BACKGROUND**

Omalizumab is a monoclonal antibody with indication for chronic idiopathic urticaria (CIU). Adequate optimization of omalizumab use could provide an improvement of efficiency without affecting the effectiveness of this therapy.

**AIM**

To describe the effectiveness and efficiency data of an optimization program about use of omalizumab for CIU.

---

**MATERIAL AND METHODS**

**Patients**

- **CIU included in a program to optimize use of omalizumab**

**DATA:** Farmatools® application and digital clinical history

- Duration of treatments
- Type of optimization (dose reduction, therapy discontinuation or both)
- Urticaria Activity Score during a 7-day period (UAS7) and costs of therapies.

**Optimization**

Optimization of treatment through treatment discontinuations or dose reduction was applied in patients with DC and TR.

---

**RESULTS**

- **Patients:** 47 patients
- **Median duration of therapy with omalizumab:** 18 months
- **Optimization of omalizumab treatment:** 61.7% of patients
  - 2.1% patients only presented dose reduction
  - 23.4% discontinuation of treatment
  - 36.2% of patients had both

- **At baseline:** all patients presented NR (UAS7>15)

**EFFECTIVENESS**

<table>
<thead>
<tr>
<th>Months</th>
<th>Patients with DC and TR</th>
<th>UAS7 NR</th>
<th>UAS7 MD</th>
<th>UAS7 DC</th>
<th>UAS7 TR</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td></td>
<td>20%</td>
<td>16%</td>
<td>8%</td>
<td>56%</td>
</tr>
<tr>
<td>18</td>
<td></td>
<td>18.7%</td>
<td>6.3%</td>
<td>31.3%</td>
<td>43.7%</td>
</tr>
<tr>
<td>36</td>
<td></td>
<td>18%</td>
<td>16%</td>
<td>8%</td>
<td>56%</td>
</tr>
</tbody>
</table>

**Total economic savings** associated with optimization of treatment with omalizumab ➔ 286150€:

- 113402€ saved through dose reduction
- 172747€ saved through therapy discontinuation

---

**CONCLUSION**

Our omalizumab optimization program for CIU provided high efficiency, maintaining nearly half of patients with TR at 36 months

---

**CONTACT DATA**

E-mail: mangilsie@yahoo.com